Dysregulated circRNAs serve as prognostic and diagnostic markers in osteosarcoma by sponging microRNA to regulate the downstream signaling pathway
Dysregulated circRNAs serve as prognostic and diagnostic markers in osteosarcoma by sponging microRNA to regulate the downstream signaling pathway
复制标题
DOI：
10.1002/jcb.29418
复制
发表时间：
2019-10-23
影响因子：
4
通讯作者：
Shao, Zengwu
中科院分区：
文献类型：
--
作者：
Huang, Xin;Yang, Wenbo;Shao, Zengwu
环状rna （circRNAs）在许多肿瘤中得到了广泛的研究。本研究的目的是证明环状rna与骨肉瘤患者的临床特征、预后和诊断之间的关系。我们主要纳入了circRNAs表达与骨肉瘤的研究。比值比（ORs）和95%置信区间（CIs）用于临床特征、敏感性和特异性，而风险比（hr）和95% ci用于评估总生存期（OS）。本研究共纳入13篇文章，其中临床特征9篇，预后11篇，诊断5篇。结果显示，circRNAs表达增加与不良临床特征显著相关。在预后方面，致癌circRNAs对总生存期有不利影响（OS: HR=2.54; 95%Cl: 2.05-3.03），而抑癌circRNAs表达增加可延长生存期（OS: HR=0.42; 95%Cl: 0.210.64）。我们的研究进一步表明，区分骨肉瘤患者和健康对照的AUC为0.85，敏感性为80%，特异性为77%。综上所述，环状rna可能是骨肉瘤患者预后评估和早期诊断的新指标。
Circular RNAs (circRNAs) have been extensively studied in many tumors. The aim of this study was to demonstrate the relationship between circRNAs and clinical features, prognosis, and diagnosis of osteosarcoma patients. We mainly included studies about circRNAs expression and osteosarcoma. The odds ratio (ORs) and 95% confidence intervals (CIs) were used for clinical features, sensitivity, and specificity, while the hazard ratios (HRs) and 95% CIs were used to assess overall survival (OS). A number of 13 articles were included in this study, including 9 about clinical features, 11 about prognosis, and 5 about diagnosis. The results showed that increased circRNAs expression was significantly correlated with adverse clinical characteristics. In terms of prognosis, oncogenic circRNAs had adverse effects on overall survival (OS: HR=2.54; 95%Cl: 2.05-3.03), and increased expression of cancer-suppressor circRNAs prolonged survival (OS: HR=0.42; 95%Cl: 0.210.64). Our study further showed an AUC of 0.85, with an 80% sensitivity and 77% specificity to distinguish osteosarcoma patients from healthy controls. In conclusion, circRNAs may be new promising indicators for prognostic evaluation and early diagnosis of osteosarcoma patients.